TIL
What one share of Instil Bio holds
Biological Products, (No Diagnostic Substances)
In January 2026 we announced our wholly owned subsidiary, Axion Bio, Inc., or Axion Bio, was discontinuing development of our former lead product candidate, AXN-2510, a bispecific antibody targeting both programmed death-ligand 1 and the family of vascular endothelial growth factors in solid tumor cancers.
Instil Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.32 |
|---|---|
| Profit | −$4.47 |
| Cash and investments | $0.82 |
| Book value | $15.83 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.17 | −$47.18 | $63.53 | −$100.55 | — | −$38.46 |
| 2021 | $0.00 | −$29.59 | $10.91 | −$33.96 | — | $86.06 |
| 2022 | — | −$34.46 | $13.06 | −$40.88 | — | $55.91 |
| 2023 | $0.00 | −$24.00 | $3.18 | −$15.79 | — | $34.72 |
| 2024 | $0.66 | −$11.39 | $0.00 | −$8.56 | — | $25.96 |
| 2025 | $1.34 | −$10.70 | — | −$5.49 | — | $16.79 |